CBL Stock Overview
Engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Control Bionics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.06 |
| 52 Week High | AU$0.10 |
| 52 Week Low | AU$0.037 |
| Beta | 0.17 |
| 11 Month Change | -4.76% |
| 3 Month Change | -32.58% |
| 1 Year Change | 39.53% |
| 33 Year Change | -85.71% |
| 5 Year Change | n/a |
| Change since IPO | -94.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| CBL | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -4.8% | 0.5% | 0.9% |
| 1Y | 39.5% | 14.8% | 18.4% |
Return vs Industry: CBL exceeded the Australian Medical Equipment industry which returned 14.8% over the past year.
Return vs Market: CBL exceeded the Australian Market which returned 18.4% over the past year.
Price Volatility
| CBL volatility | |
|---|---|
| CBL Average Weekly Movement | 10.6% |
| Medical Equipment Industry Average Movement | 9.4% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: CBL has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: Insufficient data to determine CBL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Jeremy Steele | www.controlbionics.com |
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. The company offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. It also provides Cosmos Connect, a small portable control device that can be used with a Windows display device; NeuroNode, a wireless wearable sensor that gives the user the ability to access their technology by bioelectric signals or spatial movements; Uno Touch, a speech generating device; and NeuroNode Duo, a wireless sensor.
Control Bionics Limited Fundamentals Summary
| CBL fundamental statistics | |
|---|---|
| Market cap | AU$14.85m |
| Earnings (TTM) | -AU$5.91m |
| Revenue (TTM) | AU$5.35m |
2.8x
P/S Ratio-2.5x
P/E RatioIs CBL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBL income statement (TTM) | |
|---|---|
| Revenue | AU$5.35m |
| Cost of Revenue | AU$1.45m |
| Gross Profit | AU$3.90m |
| Other Expenses | AU$9.81m |
| Earnings | -AU$5.91m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.024 |
| Gross Margin | 72.82% |
| Net Profit Margin | -110.52% |
| Debt/Equity Ratio | 8.3% |
How did CBL perform over the long term?
See historical performance and comparison